Annex I

Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s)

Scientific conclusions

Taking into account the PRAC Assessment Report on the PSUR(s) for leuprorelin, the scientific conclusions are as follows:

In December 2016, a signal on Interstitial Lung Disease was raised by the French regulatory authority and the MAH Takeda provided the cumulative review of cases. Based on the evaluation of the 87 submitted cases (including 11 fatal cases), a causal relationship cannot be excluded for some of them. Therefore, based on available data regarding “Interstitial Lung Disease", the PRAC considers that changes to the product information (section 4.8 of the SmPC and section 4 of the product leaflet) of the medicinal products containing leuprorelin, are warranted.

The CMDh agrees with the scientific conclusions made by the PRAC.

Grounds for the variation to the terms of the Marketing Authorisation(s)

On the basis of the scientific conclusions for leuprorelin the CMDh is of the opinion that the benefit-risk balance of the medicinal product(s) containing leuprorelin is unchanged subject to the proposed changes to the product information.

The CMDh reaches the position that the marketing authorisation(s) of products in the scope of this single PSUR assessment should be varied. To the extent that additional medicinal products containing leuprorelin are currently authorised in the EU or are subject to future authorisation procedures in the EU, the CMDh recommends that the concerned Member States and applicant/marketing authorisation holders take due consideration of this CMDh position.

Annex II

Amendments to the product information of the nationally authorised medicinal product(s)

Amendments to be included in the relevant sections of the Product Information (new text **underlined and in bold**, deleted text ~~strike through~~)>

Summary of Product Characteristics

- Section 4.8

The following adverse reaction(s) **Interstitial lung disease** should be added under the SOC **Respiratory, thoracic and mediastinal disorders** with a frequency **Not Known**

Package Leaflet

PL

4. POSSIBLE SIDE EFFECTS

Not known (frequency cannot be estimated from available data)

Inflammation of lungs, lung disease

Annex III

Timetable for the implementation of this position

Timetable for the implementation of this position

Adoption of CMDh position:	April 2018 CMDh meeting
Transmission to National Competent Authorities of the translations of the annexes to the position:	9 June 2018
Implementation of the position by the Member States (submission of the variation by the Marketing Authorisation Holder):	8 August 2018